Drug intelligence / Profile preview

177Lu-FC516

Development stage: Phase 1
Lead developer: FindCure Biosciences
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

177Lu-FC516 is an investigational radiopharmaceutical developed by FindCure Biosciences for the treatment of prostate cancer. It consists of the beta-emitting radioisotope Lutetium-177 (177Lu) conjugated to FC516, a targeting ligand that binds with high affinity to Prostate-Specific Membrane Antigen (PSMA). PSMA is a cell-surface protein that is significantly overexpressed in prostate cancer cells, particularly in metastatic and castration-resistant stages. Upon intravenous administration, the 177Lu-FC516 complex binds to PSMA-expressing tumor cells and is internalized. The localized emission of beta radiation from the 177Lu isotope induces DNA damage and subsequent apoptosis in the targeted cancer cells while minimizing exposure to surrounding healthy tissue. The drug is currently being evaluated in Phase 1 clinical trials to determine its safety profile, radiation dosimetry, and preliminary therapeutic efficacy.

Other names: Lutetium (177Lu) FC516 Injection

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on 177Lu-FC516.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 177Lu-FC516.

Explore the full profile